As shown in the Table 4, neo-adjuvant therapy, tumor > 2.0 cm, LVI were unfavorable prognostic factor in multivariate analysis, while endocrine therapy (HR 0.41, 95% CI: 0.26–0.62, P <  0.001) and HER2-pos-T (HR 0.56, 95% CI: 0.36–0.89, P = 0.013) were associated with significantly better DFS. The gene discussed is ERBB2; the disease is neoplasm.